Drug discovery

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Protein chemistry / Proteomics #RNA #Screening #Stem cells

Hit to lead and lead to candidate optimisation using multi-parametric principles

Hit to lead and lead to candidate optimisation using multi-parametric principles By Dr Anthony D. Baxter and Dr Peter M. Lockey As the numbers of potential target proteins become available for pharmaceutical companies of all sizes, the drive towards more cost-effective drug discovery assumes greater significance. It is a truism… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Clinical trials #Drug development #Drug discovery #Genomics #High Content Screening #High throughput screening #Lead discovery #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation

Data Mining in the pharmaceutical industry

Data Mining in the pharmaceutical industry By Dr Robert D. Small and Herbert A. Edelstein A research-based pharmaceutical company is a data accumulating wonder. More than in any other industry, success is predicated on the collection, processing and exploitation of that data. This is not always recognised and often not… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Cell culture #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Precision medicine #Regulatory #RNA #Screening #Sequencing #Therapeutics #Toxicology

Evaluating future drug candidates and their manufacture together

Evaluating future drug candidates and their manufacture together By Professor Peter Dunnill Classically, evaluating a candidate drug has preceded evaluation of the process for making it. The late rush to process development worked reasonably well with simple chemical pharmaceuticals. With complex biopharmaceuticals, a new approach is needed. One now being… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Organic chemistry #PCR #Protein chemistry / Proteomics #Screening #Sequencing #System biology

Chemogenomics – A gene family approach to parallel drug discovery

Chemogenomics - A gene family approach to parallel drug discovery By Dr Paul R. Caron, Dr Michael D. Mullican, Dr Robert D. Mashal, Dr Keith P. Wilson, Dr Michael S. Su and Dr Mark A. Murcko Currently available drugs only target around 500 different proteins (4). Recent reports from efforts… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Lead optimisation #Microfluidics #Patent Law #PCR #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA #Screening

The lab on a chip and its impact on drug discovery

The lab on a chip and its impact on drug discovery by Dr Simon Cowen and Dr Coulton Legge Few technology developments have had as profound an effect on society as the invention of the microchip integrated circuit in the 1960s. Since then, the power of electronic circuits has increased… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Business #Drug development #Drug discovery #High Content Screening #Lead discovery #RNA

Why pharmaceutical companies should teach scientists to be entrepreneurs

Why pharmaceutical companies should teach scientists to be entrepreneurs By Dr Jeffrey P. Kiplinger Conventional wisdom says that big employers do not want anything to do with entrepreneurs as employees. The last thing a human resources director wants to see on a resume is that a candidate started a business… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Pathology #Pharmacogenomics #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Target validation

The Impact of Genomics on Regulation

The Impact of Genomics on Regulation By Dr Steve Arlington, Dr Tim Peakman, Adriana Salvatore and Jonathan Peachey Advances in science and technology are enabling us to understand physiology and pathology at a totally new level; to define, subtype and track diseases much more accurately; and to treat patients far… Read More

#Archive

#Analysis #Animal models #Automation / robotics #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Lead discovery #Molecular medicine #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #System biology #Target validation #Therapeutics #Toxicology

New Developments in Analgesia

New Developments in Analgesia By Dr Susan Boyce, Dr Zahid Ali and Dr Raymond G. Hill Novel therapies for pain and headache are major medical needs and constitute a continued opportunity. Novel treatments are likely to arise from a better understanding of both the pathophysiology of clinical pain conditions and… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Cell therapy #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Lead discovery #Regulatory #RNA

Health economic considerations for early drug discovery

Health economic considerations for early drug discovery By Dr Ann-Marie Craig and Dr Lisa Kennedy The use of health economics in early phase development, while not an exact science, can, when conjoined with clinical evidence, be a very valuable information tool enabling companies to identify whether there is a market… Read More

#Archive

#Animal models #Assay development optimisation & technology #Biochemistry #Biomarkers #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Imaging #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Toxicology

Surrogate Endpoints In Cancer Trials

Surrogate Endpoints In Cancer Trials By Professor Karol Sikora Over the next 20 years systematic programmes of cancer risk assessment will be established and cancer-preventive drugs will be developed. The ability to prevent cancer will dramatically increase the number of people who will need to regularly attend clinics. This article… Read More

#Archive

#Analysis #Business #Cell therapy #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Molecular medicine #Pharmacogenomics #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Protein Arrays – New technology for the proteomics era

Protein Arrays - New technology for the proteomics era By Dr Jeffrey P. Kiplinger The study of the human proteome will drive drug discovery in coming years; although how, when, and in what direction are a little uncertain at present. To build understanding of the role of the human protein… Read More

#Archive

#ADME / Tox #Analysis #Automation / robotics #Biomarkers #Business #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genomics #High throughput screening #Immunology #Lead discovery #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Toxicology

Unrealised wealth in the avalanche of science

Unrealised wealth in the avalanche of science By Dr Benjamin P. Chen The human genome information complemented with high throughput screening, proteomics and molecular structure analysis has significantly increased the speed at which potential drug leads are identified. The Pandora's box of intellectual properties opened as a result is beyond… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Business #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #Genomics #Lead discovery #Lead optimisation #RNA #Target validation

Outsourcing life science informatics solutions

Outsourcing life science informatics solutions By Dr Steve Gardner The life science industry depends on information gathered from new technologies for productivity and competitive advantage in the R&D process. As more information is gathered and the systems become more complex, building and maintaining data management solutions that support rapid and… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Pharmacogenomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Regenerative Medicine – Promising answers in the face of an ageing population

By Dr Doros Platika As the population ages, the scientific and medical communities are working to solve the challenges this changing demographic will place on society. Companies involved in the promising field of regenerative medicine are now on the cutting edge as it strives to promote longevity without disability. Regenerative… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Patent Law #Pharmacology #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Protein Therapeutics – New ladders up the fruit tree

Protein Therapeutics - New ladders up the fruit tree By Dr Richard AG Smith Therapeutic proteins are often regarded as too technologically demanding, too costly, too restricted in routes or duration of administration or - in an era of massive opportunity provided by high throughput screening, combinatorial chemistry and genomics… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Animal models #Automation / robotics #Business #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Pharmacogenomics #Regulatory #RNA #Screening #Target validation #Toxicology

Biologically Relevant Chemistry

Biologically Relevant Chemistry By Dr Stephen A. Hill A large proportion of R&D expenditure relates to the investigation of compounds which ultimately fail to reach the market as useful medicines. We discuss why early drug discovery - using high throughput, automated in vitro and in silico methods, must become the… Read More

#Archive